$3.96 Million in Sales Expected for Crispr Therapeutics AG (NASDAQ:CRSP) This Quarter

Share on StockTwits

Wall Street analysts expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post sales of $3.96 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Crispr Therapeutics’ earnings, with estimates ranging from $250,000.00 to $14.80 million. Crispr Therapeutics reported sales of $211.93 million in the same quarter last year, which indicates a negative year over year growth rate of 98.1%. The business is expected to report its next earnings results on Monday, October 26th.

On average, analysts expect that Crispr Therapeutics will report full-year sales of $7.19 million for the current year, with estimates ranging from $200,000.00 to $29.90 million. For the next financial year, analysts anticipate that the business will report sales of $38.67 million, with estimates ranging from $3.50 million to $90.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, July 27th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.35). Crispr Therapeutics had a return on equity of 2.35% and a net margin of 6.77%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $19.77 million. During the same period in the previous year, the firm earned ($1.01) earnings per share. Crispr Therapeutics’s revenue was down 86.2% on a year-over-year basis.

Several research firms have issued reports on CRSP. Canaccord Genuity lifted their price target on shares of Crispr Therapeutics from $80.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. SunTrust Banks assumed coverage on Crispr Therapeutics in a report on Tuesday, July 14th. They issued a “buy” rating and a $140.00 target price on the stock. Needham & Company LLC upped their price objective on shares of Crispr Therapeutics from $84.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Roth Capital boosted their price target on shares of Crispr Therapeutics from $100.00 to $105.00 and gave the company a “buy” rating in a report on Friday, June 19th. Finally, William Blair restated a “buy” rating on shares of Crispr Therapeutics in a research report on Tuesday, July 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $90.93.

In related news, COO Lawrence Otto Klein sold 65,088 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $75.93, for a total value of $4,942,131.84. Following the transaction, the chief operating officer now owns 58,666 shares in the company, valued at $4,454,509.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael John Tomsicek sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $92.26, for a total transaction of $1,107,120.00. Following the completion of the sale, the chief financial officer now directly owns 12,410 shares of the company’s stock, valued at $1,144,946.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 284,246 shares of company stock valued at $23,578,888. Insiders own 21.40% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CRSP. Capital Advisors Inc. OK grew its stake in shares of Crispr Therapeutics by 2.2% in the second quarter. Capital Advisors Inc. OK now owns 136,497 shares of the company’s stock worth $12,686,000 after acquiring an additional 2,918 shares during the last quarter. Handelsbanken Fonder AB acquired a new stake in Crispr Therapeutics in the 2nd quarter worth $441,000. Stephens Inc. AR bought a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $643,000. Private Advisor Group LLC raised its position in shares of Crispr Therapeutics by 7.0% during the second quarter. Private Advisor Group LLC now owns 5,207 shares of the company’s stock valued at $383,000 after buying an additional 340 shares during the last quarter. Finally, Orbimed Advisors LLC raised its position in shares of Crispr Therapeutics by 26.5% during the second quarter. Orbimed Advisors LLC now owns 697,524 shares of the company’s stock valued at $51,261,000 after buying an additional 146,324 shares during the last quarter. 55.29% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CRSP traded down $3.67 during mid-day trading on Thursday, hitting $82.02. The company’s stock had a trading volume of 1,570,215 shares, compared to its average volume of 874,703. Crispr Therapeutics has a fifty-two week low of $32.30 and a fifty-two week high of $105.12. The stock has a market capitalization of $5.76 billion, a price-to-earnings ratio of 178.30 and a beta of 2.29. The firm has a 50-day moving average price of $90.72 and a 200 day moving average price of $65.65.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: How does a 12b-1 fee affect fund performance?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply